Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
710 (USA) · Dr. Silva
consented 2012-11-10
AEs
1
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-23 (study day 44.0); relationship: POSSIBLE
Data queries
No data queries.